Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lichen Planus Clear all
Recruiting Phase 4 Interventional

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

NCT07396168
View directory record Official record
Conditions
Lichen Plano-Pilaris
Interventions
Nemolizumab
Drug
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634
View directory record Official record
Conditions
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions
KPL-716, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational

Methods Validation Assessment for Study of Inflammatory Skin Disease

NCT03796806
View directory record Official record
Conditions
Lichen Planus
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

NCT04300296
View directory record Official record
Conditions
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Interventions
secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jul 23, 2026, 5:45 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

NCT06158113
View directory record Official record
Conditions
Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus
Interventions
Baricitinib 4 milligram Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Valchlor in the Treatment of Lichen Planopilaris

NCT03417141
View directory record Official record
Conditions
Lichen Planopilaris
Interventions
Mechlorethamine 0.016% Top Gel
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jul 23, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus

NCT00135733
View directory record Official record
Conditions
Lichen Planus
Interventions
Amevive (Alefacept), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2009 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Dexamethasone to Treat Oral Lichen Planus

NCT00111072
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
dexamethasone 0.01% solution
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Evaluation and Treatment of Oral Soft Tissue Diseases

NCT00001601
View directory record Official record
Conditions
Aphthous Stomatitis, Burning Mouth Syndrome, Lichen Planus, Mouth Disease, Temporomandibular Joint Disorder
Interventions
Electrocardiogram, Biopsies, Diagnostic imaging
Procedure
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Research Core Dental Screening Protocol

NCT00090818
View directory record Official record
Conditions
Oral Mucosal Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 5:45 AM EDT
Not listed No phase listed Observational

Design and Validation of a New Assessment Tool for Lichen Planopilaris

NCT03082560
View directory record Official record
Conditions
Lichen Planopilaris of Scalp, Lichen Plano-Pilaris, Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions
Boston Grade of Activity in Lichen Planopilaris
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

NCT03592342
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Clobetasol Propionate
Drug
Lead sponsor
Dermtreat
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hialeah, Florida • Miami, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus

NCT00102557
View directory record Official record
Conditions
Lichen Planus, Oral
Interventions
Hydroxychloroquine
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus

NCT00525421
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Curcuminoids, Placebo
Drug
Lead sponsor
Nita Chainani Wu
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Early Phase 1 Interventional

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668
View directory record Official record
Conditions
Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
Interventions
Topical gabapentin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 23, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Topical Ruxolitinib Lichen Planus

NCT03697460
View directory record Official record
Conditions
Lichen Planus
Interventions
INCB018424
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Jul 23, 2026, 5:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

NCT00691769
View directory record Official record
Conditions
Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
30 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jul 23, 2026, 5:45 AM EDT
Terminated No phase listed Observational

Vulvar Mucosal Specialty Clinic Chart Review

NCT02881229
View directory record Official record
Conditions
Vulvar Disease, Lichen Sclerosus, Lichen Planus, Vulvodynia
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Jul 23, 2026, 5:45 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating LP-10 in Subjects With OLP

NCT06233591
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
LP-10 (Liposomal Tacrolimus)
Drug
Lead sponsor
Lipella Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Fremont, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 23, 2026, 5:45 AM EDT